Our recent work indicates that valproic acid, an FDA approved HDAC inhibitor for treatment bipolar disorder, protects heart function after I/R injury by promoting a Foxm1-mediated transcriptional pathway Tian et al., 2019. This evidence concerns the gene FOXM1 and bipolar disorder.